+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-25Number of Pages: 131

Porcine Vaccine Market (Disease Indication - Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), and Porcine Circovirus Associated Disease (PCVAD); End User - Veterinary Hospitals and Hog/Pig Production Farms; Technology - Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines) - North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

North America Porcine Vaccine Market: Snapshot

For several decades, vaccination has remained one of the most important interventions for disease prevention among humans and animals. In veterinary medicine, vaccination has proven to be a boon for animal health. Diseases such as diarrhoea, swine influenza, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD), have been greatly reduced from spreading endemic in several cases. Some diseases such as foot and mouth disease and cholera high fever in swines have been significantly eliminated in North America with the help of vaccination. 

The market for porcine vaccine in the region is expected to exhibit healthy growth in the next few years as well. The rising demand for meat and gelatin and concerns regarding the rising pace of occurrence of zoonotic diseases will be the key factors driving the market in the near future. Transparency Market Research estimates that the North America porcine vaccine market will expand at a 5.3% CAGR from 2016 to 2024. As a result, the market, which valued at US$540.9 mn in 2015, will rise to US$926.2 mn by 2024. 

Inactivated Vaccines to Remain Most Preferred

In terms of the technology used to develop vaccines, the North America porcine vaccines market has been segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, DNA vaccines, and conjugate vaccines. Of these, the segment of inactivated vaccines dominated the market in 2015 and is expected to account for a 53.3% of the North America veterinary vaccine market in 2016. The segment is also expected to exhibit the most promising growth in the near future, expanding at a 6.7% CAGR over the period between 2016 and 2024. 

The segment of live attenuated vaccines will exhibit a strong 5.9% CAGR over the said period. Rise in the number of swine farms, rising prevalence of zoonotic disease, and increase in investments by key players are likely to drive the live attenuated vaccine segment. The DNA vaccine segment is projected to emerge as a high-growth segment owing to rise in demand and increase in R&D investments. DNA vaccines have shown excellent results in granting strong immunity against homologous infections and have a good score in terms of approval from regulatory bodies in the region. As a result, the demand for these vaccines is expected to rise at a healthy pace in the region over the forecast period. porcine vaccine marketU.S. Market to Continue to Account for Dominant Chunk in Sales

The North America porcine vaccine market has been examined for two countries in the region: the U.S. and Canada. The U.S. market for porcine vaccines accounted for a larger 63% share in the North America market in 2015. The U.S. porcine vaccine market is expected to exhibit the most lucrative 6.6% CAGR over the period between 2016 and 2024. Factors such as well-established infrastructure in immunological research, high concentration of key players, highly organized farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners are attributed to the dominant share of the country in the North America market. 

The market in Canada is also anticipated to expand at a healthy, but comparatively lower CAGR of 5.8% from 2016 to 2024. Factors such as the rising prevalence of PRRS virus and PCV2 among herds and rising focus of key players on R&D activities for the development of effective vaccines will contribute to the growth prospects of the Canada porcine vaccines market in the near future. Moreover, export and import permits among contract manufacturers or distributer firms and low estimated cost of products are also expected to make the porcine vaccine market more popular in Canada. 

Some of the key players in the market are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Merck & Co., Inc., Merial (Sanofi), Vetoquinol, Zoetis, Inc., Elanco (Eli Lilly and Company). 

North America Porcine Vaccine Market: Scope of the Report 

This report on the porcine vaccine market analyzes the current and future scenario of the North America market. Increase in disease indication among swine, technological advancement of RNA strand methodology, and cultivation of pig for growth in standard of living is accounted to form growth in porcine vaccine segment.   Increase trading facilities of live hogs/pigs, demand of pork meat and innovation through clinical research activities are some of the drivers expected to drive the North America porcine vaccine market during the forecast period. 

The North America porcine vaccine market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the country’s market with respect to the segments based on disease indication, technology, end-user, and country. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the North America porcine vaccine market. 

North America Porcine Vaccine Market: Segmentation 

Based on disease indication, the market has been segmented into diarrhoea, swine influenza, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD) and others. Diarrhoea is the most widely spread disease across the North America; porcine epidemic diarrhea virus (PEDV) hit the United States in 2013 and spread to Canada in 2014 which infected piglets and has 80%-100% mortality rate. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference from veterans for treating the swine with various disease indications. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year. 

Based on technology, the North America porcine vaccine market has been segmented into inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. The market segments have been extensively analyzed based on increase in demand for disease treatment such as PEDv, PRRSv, and PCVAD. Demand of disease free pork meat, and increasing awareness for treating the cultivated pigs are driving the market share of technological segment. Different types of end-user utilize porcine vaccines to treat swine diseases either. Under the end-user segment, hog/pig production farms plays a major role followed by veterinary hospitals. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year. 

North America Porcine Vaccine Market: Geographical and Competitive Dynamics 

Geographically, the North America porcine vaccine market has been categorized into key countries: North America (the U.S. and Canada). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year. 

The report also profiles major players in the North America porcine vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., Merial (Sanofi), Vetoquinol, Zoetis Inc. and others. 

The North America porcine vaccine market has been segmented as follows: 

North America Porcine Vaccine Market, by Disease Indication

  • Diarrhoea
  • Swine Influenza
  • Arthritis
  • Bordatella Rhinitis
  • Porcine Reproductive and Respiratory Virus (PRRSV)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

North America Porcine Vaccine Market, by Technology

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • DNA Vaccines

North America Porcine Vaccine Market, by End-user

  • Veterinary Hospitals
  • Hog/Pig Production Farm

North America Porcine Vaccine Market, by Country

  • North America
    • U.S.
    • Canada


 
 
Back To Top